|
||||||||||
|
You are here: Published Weight Loss Studies >
Author: Min B, McBride BF, Kardas MJ, Ismali A, Sinha V, Kluger J, White CM
Author affiliation: School of Pharmacy, University of Connecticut, Storrs, 06102, USA.
Publication date & source: 2005.05, Pharmacotherapy., 25(5):654-9.
Publication type: Clinical Trial; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
STUDY OBJECTIVE: Metabolife 356, an ephedra-containing weight-loss product, substantially increases the corrected QT (QTc) interval. Metabolife Ephedra Free, a similar supplement, contains caffeine and extracts of green tea, garcinia cambogia, and yerba mate. Its electrocardiographic (ECG) effects are not known. Therefore, we sought to determine the effect of this supplement on the QTc interval. DESIGN: Randomized, double-blind, placebo-controlled, crossover study. SETTING: University of Connecticut, Storrs Campus. SUBJECTS: Twenty healthy volunteers. Intervention. A single capsule containing half the normal recommended dose of Metabolife Ephedra Free or matching placebo was administered in crossover fashion, with a 7-day washout period between treatments. MEASUREMENTS AND MAIN RESULTS: Baseline and three postdose ECG measurements were obtained, and QTc intervals were measured over a 5-hour study period. No significant differences in the QTc interval or other ECG variables were observed between the Metabolife Ephedra Free and placebo groups. CONCLUSION: At half the recommended single dose, Metabolife Ephedra Free does not affect the QTc interval or other ECG variables over 5 hours. Dose-response studies and studies of longer duration should be conducted.
|
|
|||||||||||||||||||||||||||||||||
|
Copyright © 2006 by Weight-Loss-Science.com All inormation is for education purposes only and should not be considered as a medical advice. |
|||||||||||||||||||||||||||||||||||